In vivo binding of 3,3'-dichlorobenzidine to rat and mouse tissue DNA

Cancer Lett. 1990 Sep;53(2-3):197-204. doi: 10.1016/0304-3835(90)90214-i.

Abstract

The kinetics of total DNA adducts were compared in the liver, bladder epithelium and small intestinal epithelium of rats and mice following a single oral dose (100 mg/kg) of 3,3'-dichlorobenzidine [( 14C]DCB). Peak DNA binding (expressed as pmol DCB bound/mg DNA) in rat tissues was 153.5, 144.8 and 36.9 in the intestine, bladder and liver, respectively, whereas in mouse tissues, the binding was 72.5, 58.2 and 55.8, respectively. In either species, the half-life of the DNA adducts in the liver (13.5 and 13.8 days in rats and mice, respectively) was comparable to that in the bladder epithelium (14.8 and 12.7 days in rats and mice, respectively) but longer than that in the intestinal epithelium (5.9 and 4.7 days in rats and mice, respectively). Peak total DCB binding in hepatic but not intestinal or bladder epithelial DNA correlated positively with total urinary DCB metabolites. In vitro, mouse hepatic S9 was 57% more active in catalyzing the formation of DNA-binding derivatives of DCB, in parallel with the higher in in vivo maximum hepatic DNA binding in mice than in rats. Thus, a single oral dose of DCB in rats and mice leads to extensive binding of the chemical to tissue DNA, with the rate of removal of the adducts not differing between target and non-target tissues.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 3,3'-Dichlorobenzidine / chemistry*
  • 3,3'-Dichlorobenzidine / metabolism
  • 3,3'-Dichlorobenzidine / pharmacokinetics
  • Animals
  • Biotransformation
  • DNA Damage*
  • DNA* / chemistry
  • Dose-Response Relationship, Drug
  • Intestinal Mucosa / metabolism
  • Liver / metabolism
  • Mice
  • Rats
  • Time Factors
  • Urinary Bladder / metabolism
  • Urine

Substances

  • 3,3'-Dichlorobenzidine
  • DNA